Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Figure 1 Median progression-free survival and overall survival for the general population and subgroups receiving anlotinib combined with nab-ptx as second-line or above treatment for advanced gastric cancer. A and B: Median progression-free survival (PFS) and overall survival (OS) for the general population, respectively; C and D: Comparisons of PFS and OS between patients with and without adverse events (AEs) during the entire treatment (with AEs vs without AEs). mPFS: Median progression-free survival; mOS: Median overall survival; sAE: Any AE including hypertension, proteinuria, and hand-foot syndrome.